Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02...

NORCROSS, Ga., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today announced additional...

GR-MD-02: Keytruda’s Partner

Introduction Merck’s (MRK) Keytruda, a PD-1 inhibitor, is quickly becoming the most broadly-used cancer treatment worldwide. EvaluatePharma projects revenue of over $12 billion by 2024,...

Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for its...

Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis

NORCROSS, Ga., June 27, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced...